Cowen & Co. Sticks to Its Buy Rating for Mersana Therapeutics Inc

By Austin Angelo

In a report released today, Boris Peaker from Cowen & Co. maintained a Buy rating on Mersana Therapeutics Inc (NASDAQ: MRSN). The company’s shares opened today at $16.92.

According to, Peaker is a 5-star analyst with an average return of 19.0% and a 53.5% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Corvus Pharmaceuticals Inc, Stemline Therapeutics Inc, and Jounce Therapeutics Inc.

Mersana Therapeutics Inc has an analyst consensus of Moderate Buy, with a price target consensus of $26.

Based on Mersana Therapeutics Inc’s latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $3.26 million and GAAP net loss of $13.97 million. In comparison, last year the company earned revenue of $4.29 million and had a GAAP net loss of $8.06 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Mersana Therapeutics, Inc. engages in the development and manufacture of antibody drug conjugates to improve patient outcomes in multiple oncology indications. Its lead product candidates are XMT-1522, which focuses on breast cancer and non-small cell lung cancer (NSCLC); and XMT-1536, which targets ovarian cancer and NSCLC.